Last reviewed · How we verify
CDD Plus Bortezomib
CDD Plus Bortezomib combines a chemotherapy regimen (CDD) with bortezomib, a proteasome inhibitor that blocks protein degradation to trigger cancer cell death.
CDD Plus Bortezomib combines a chemotherapy regimen (CDD) with bortezomib, a proteasome inhibitor that blocks protein degradation to trigger cancer cell death. Used for Multiple myeloma (in combination with chemotherapy), Lymphoma (investigational).
At a glance
| Generic name | CDD Plus Bortezomib |
|---|---|
| Also known as | Chemotherapy Plus Bortezomib |
| Sponsor | Beijing Chao Yang Hospital |
| Drug class | Proteasome inhibitor combined with chemotherapy |
| Target | 26S proteasome |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bortezomib inhibits the 26S proteasome, preventing degradation of pro-apoptotic proteins and leading to accumulation of cellular stress and apoptosis in cancer cells. The CDD component (likely a chemotherapy combination) provides additional cytotoxic activity. Together, this combination targets multiple pathways to enhance anti-tumor efficacy.
Approved indications
- Multiple myeloma (in combination with chemotherapy)
- Lymphoma (investigational)
Common side effects
- Peripheral neuropathy
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |